Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 2/20 | 0.52 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.52 |
| ▸ | MAP4K2 | Q12851 | 2/20 | 0.52 |
| ▸ | SYK | P43405 | 1/20 | 0.48 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.46 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.46 |
| ▸ | RAF1 | P04049 | 12/20 | 0.45 |
| ▸ | BRAF | P15056 | 11/20 | 0.45 |
| ▸ | LYN | P07948 | 3/20 | 0.44 |
| ▸ | INSR | P06213 | 2/20 | 0.44 |
| ▸ | LCK | P06239 | 2/20 | 0.44 |
| ▸ | HCK | P08631 | 2/20 | 0.44 |
| ▸ | SRC | P12931 | 2/20 | 0.44 |
| ▸ | KDR | P35968 | 2/20 | 0.44 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13437981 | 0.93 | SYK (0.46) | CSF1RTNK2MAP4K2SYKRAF1 | |
| SCHEMBL502120 | 0.92 | LYN (0.52) | CSF1RTNK2MAP4K2SYKRAF1 | |
| SCHEMBL10071825 | 0.91 | SYK (0.45) | CSF1RTNK2MAP4K2SYKRAF1 | |
| SCHEMBL10072018 | 0.90 | TNK2 (0.56) | CSF1RTNK2MAP4K2SYKNTRK1 | |
| SCHEMBL10072194 | 0.89 | BRAF (0.51) | CSF1RTNK2MAP4K2SYKNTRK1 | |
| SCHEMBL10071818 | 0.87 | SYK (0.45) | CSF1RTNK2MAP4K2SYKRAF1 | |
| SCHEMBL13376457 | 0.85 | NR2E1 (0.55) | CSF1RTNK2MAP4K2SYKNTRK1 | |
| SCHEMBL10043776 | 0.85 | SYK (0.65) | SYKRAF1BRAFLCKKDR | |
| SCHEMBL10071826 | 0.84 | LCK (0.53) | CSF1RTNK2MAP4K2SYKRAF1 | |
| SCHEMBL10071749 | 0.84 | SYK (0.49) | CSF1RTNK2MAP4K2SYKRAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106068-B2 | Compositions and methods for modulating c-kit and PDGFR receptors | IRM LLC (BM) | 2012-01-31 | — | — | US | disclosed |
| US-20100081656-A1 | COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS | IRM LLC (BM) | 2010-04-01 | — | — | US | disclosed |
| US-7678792-B2 | Compositions and methods for modulating c-kit and PDGFR receptors | IRM LLC (BM) | 2010-03-16 | — | — | US | disclosed |
| US-7678792-B2 | Compositions and methods for modulating c-kit and PDGFR receptors | IRM LLC (BM) | 2010-03-16 | — | — | US | disclosed |
| US-20080176846-A1 | COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS | IRM LLC (BM) | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176846-A1 | COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS | FYN, FLT3, SRC | CSF1R 89/4885TNK2 79/4885MAP4K2 17/4885 |
| US-20100081656-A1 | COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS | FYN, FLT3, SRC | CSF1R 89/4885TNK2 79/4885MAP4K2 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.